Details

Autor(en) / Beteiligte

• Siegrist, Claire-Anne
• Plotnicky-Gilquin, Hélène
• Córdova, Marco
• Berney, Monika
• Bonnefoy, Jean-Yves
• Nguyen, Thien Ngoc
• Lambert, Paul-Henri
• Power, Ultan F.

Titel

Protective Efficacy against Respiratory Syncytial Virus following Murine Neonatal Immunization with BBG2Na Vaccine: Influence of Adjuvants and Maternal Antibodies

Ist Teil von

• The Journal of infectious diseases, 1999-06, Vol.179 (6), p.1326-1333

Ort / Verlag

Chicago, IL: University Chicago Press

Erscheinungsjahr

1999

Quelle

Oxford Journals 2020 Medicine

Beschreibungen/Notizen

• Alum-adsorbed BBG2Na, a recombinant vaccine derived in part from the respiratory syncytial virus (RSV) subgroup A G protein, induced moderate antibody titers after 1 immunization in 1-week-old mice but conferred complete lung protection upon RSV challenge. The anti-BBG2Na IgG1-IgG2a neonatal isotype profile was suggestive of dominant Th2 responses compared with those in adults. Formulation of BBG2Na with a Th1-driving adjuvant efficiently shifted neonatal responses toward a more balanced and adultlike IgG1-IgG2a profile without compromising its protective efficacy. BBG2Na-induced protective immunity was maintained even after early life immunization in the presence of high titers of maternal antibodies. Under these conditions, the protective efficacy (86%–100%) reflected the high capacity of the nonglycosylated G2Na immunogen to escape inhibition by RSV-A—induced maternal antibodies. Thus, immunization with BBG2Na protected against viral challenge despite neonatal immunologic immaturity and the presence of maternal antibodies, two major obstacles to neonatal RSV vaccine development.